http://medicineworld.org/cancer/prostate/prostate-cancer-blog.html Prostate cancer blog from medicineworld.org adds a personal touch to the stories related to prostate cancer. This prostate cancer blog brings you stories of hope, stories of survivors and latest news and research related to prostate cancer. Fri, 29 Apr 2011 14:36:46 GMT en-us http://medicineworld.org/images/blogs/prostate.jpg http://medicineworld.org/cancer/blog/permalinks/Dec-2005/cure-cancer-with-your-personal-computer.html 107 99 http://medicineworld.org/stories/lead/4-2011/mri-locates-prostate-cancer-recurrence.html http://medicineworld.org/stories/lead/4-2011/mri-locates-prostate-cancer-recurrence.html Fri, 29 Apr 2011 14:36:46 GMT A pelvic MRI scan with IV contrast and rectal balloon is highly effective in identifying local recurrence even at low PSA values in patients with prostate cancer with a rising or persistently elevated PSA after prostatectomy, as per a research studypresented April 29, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA)........ ]]> http://medicineworld.org/stories/lead/4-2011/parkinsons-disease-and-prostate-cancer.html http://medicineworld.org/stories/lead/4-2011/parkinsons-disease-and-prostate-cancer.html Fri, 29 Apr 2011 14:36:46 GMT University of Utah School of Medicine scientists have found compelling evidence that Parkinson's disease is linked to an increased risk of prostate cancer and melanoma, and that this increased cancer risk also extends to close and distant relatives of individuals with Parkinson's disease. Eventhough a link between Parkinson's disease and melanoma has been suspected before, this is the first time that an increased risk of prostate cancer has been reported in Parkinson's disease........ ]]> http://medicineworld.org/stories/lead/4-2011/heart-drug-cuts-prostate-cancer-risk.html http://medicineworld.org/stories/lead/4-2011/heart-drug-cuts-prostate-cancer-risk.html Fri, 29 Apr 2011 14:36:46 GMT Johns Hopkins researchers and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The researchers say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer........ ]]> http://medicineworld.org/stories/lead/3-2011/prostate-cancer-patients-on-adt.html http://medicineworld.org/stories/lead/3-2011/prostate-cancer-patients-on-adt.html Fri, 29 Apr 2011 14:36:46 GMT Seventy per cent of men who received androgen-deprivation treatment (ADT) after surgery to remove their prostate gland gained significant weight in the first year, putting on an average of 4.2kg, as per a paper in the recent issue of the urology journal BJUI. Scientists studied the recorded weights of 132 men who underwent radical prostatectomy between 1988 and 2009 at four US Veterans Affairs Medical Centers in California, Georgia and North Carolina, before and after they received ADT........ ]]> http://medicineworld.org/stories/lead/1-2011/microrna-suppresses-prostate-cancer-stem-cells.html http://medicineworld.org/stories/lead/1-2011/microrna-suppresses-prostate-cancer-stem-cells.html Fri, 29 Apr 2011 14:36:46 GMT A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein usually found on prostate cancer stem cells. A research team led by researchers at The University of Texas MD Anderson Cancer Center reported today in an advance online publication at Nature Medicine "Our findings are the first to profile a microRNA expression pattern in prostate cancer stem cells and also establish a strong rationale for developing the microRNA miR-34a as a new therapy option for prostate cancer," said senior author Dean Tang, Ph.D., professor in MD Anderson's Department of Molecular Carcinogenesis........ ]]> http://medicineworld.org/stories/lead/7-2010/key-pathway-in-end-stage-prostate-cancer-blocked.html http://medicineworld.org/stories/lead/7-2010/key-pathway-in-end-stage-prostate-cancer-blocked.html Fri, 29 Apr 2011 14:36:46 GMT Prostate cancer advances when tumors become resistant to hormone treatment, which is the standard therapy for patients, and begin producing their own androgens. Scientists at UT Southwestern Medical Center have observed that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth........ ]]> http://medicineworld.org/stories/lead/7-2010/how-prostate-cancer-packs-a-punch.html http://medicineworld.org/stories/lead/7-2010/how-prostate-cancer-packs-a-punch.html Fri, 29 Apr 2011 14:36:46 GMT Some types of prostate tumors are more aggressive and more likely to metastasize than others. Nearly one-third of these aggressive tumors contain a small nest of particularly dangerous cells known as neuroendocrine-type cells. More rarely, some aggressive prostate tumors are made up entirely of neuroendocrine-type cells. The presence of neuroendocrine-type cancer cells is linked to a poor prognosis, but spotting these rare cells can be like finding a needle in a haystack. Now, as per a research findings reported in the July 13 issue of Cancer Cell, a team of researchers led by Ze'ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has identified a series of proteins that might make it easier for doctors to better diagnose the more metastatic forms of prostate cancer........ ]]> http://medicineworld.org/stories/lead/7-2010/whats-your-baseline-psa.html http://medicineworld.org/stories/lead/7-2010/whats-your-baseline-psa.html Fri, 29 Apr 2011 14:36:46 GMT Men who have a baseline PSA value of 10 or higher the first time they are tested are up to 11 times more likely to die from prostate cancer than are men with lower initial values, as per Duke University Medical Center researchers. Researchers say the finding, appearing early online in the journal Cancer, supports routine, early prostate-specific antigen (PSA) screening among healthy men with normal life expectancy a practice several studies have recently questioned........ ]]> http://medicineworld.org/stories/lead/6-2010/polyphenols-in-red-wine-and-green.html http://medicineworld.org/stories/lead/6-2010/polyphenols-in-red-wine-and-green.html Fri, 29 Apr 2011 14:36:46 GMT In what could lead to a major advance in the therapy of prostate cancer, researchers now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery, published online in The FASEB Journal (http://www.fasebj.org), explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate cancer growth. This finding is important because it may lead to the development of drugs that could stop or slow cancer progression, or improve current therapys........ ]]> http://medicineworld.org/stories/lead/6-2010/low-risk-prostate-cancer.html http://medicineworld.org/stories/lead/6-2010/low-risk-prostate-cancer.html Fri, 29 Apr 2011 14:36:46 GMT Johns Hopkins experts have found that men enrolled in an active surveillance program for prostate cancer that eventually needed surgery to remove their prostates fared just as well as men who opted to remove the gland immediately, except if a follow-up biopsy during surveillance showed high-grade cancer........ ]]> http://medicineworld.org/stories/lead/4-2010/study-could-improve-treatments-for-prostate-cancer.html http://medicineworld.org/stories/lead/4-2010/study-could-improve-treatments-for-prostate-cancer.html Fri, 29 Apr 2011 14:36:46 GMT Van Andel Research Institute (VARI) researchers have determined how two proteins mandatory for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved therapys for the disease. One of the proteins, androgen receptor, is already an important drug target for prostate cancer. The other, steroid receptor coactivator-3 (SRC3), was originally identified for its role in the development of breast cancer. SCR3 has also been characterized as a key factor in the development of prostate cancer, but, until now, the exact relationship between androgen receptor and SCR3 has been unclear........ ]]> http://medicineworld.org/stories/lead/2-2010/lower-detection-of-prostate-cancer.html http://medicineworld.org/stories/lead/2-2010/lower-detection-of-prostate-cancer.html Fri, 29 Apr 2011 14:36:46 GMT Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, as per a new brief communication published online February 8 in the Journal of the National Cancer Institute To compare the PSA screening performance in a clinical trial with that in a population setting, Elisabeth M. Wever, MSc, Department of Public Health, Erasmus Medical Center, the Netherlands, and his colleagues applied a microsimulation model developed for prostate cancer and screening to the European Randomized Study of Screening for Prostate Cancer (ERSPC)Rotterdam. The model was adapted by replacing the trial's demography parameters with U.S.-specific ones and the screening protocol with the frequency of PSA tests in the population. The natural progression of prostate cancer and the sensitivity (percentage of men correctly identified as having prostate cancer of those who have preclinical prostate cancer) of a PSA test followed by a biopsy were assumed to be the same in the US as in the trial........ ]]> http://medicineworld.org/stories/lead/2-2010/how-some-prostate-cancer-cells-aggressive.html http://medicineworld.org/stories/lead/2-2010/how-some-prostate-cancer-cells-aggressive.html Fri, 29 Apr 2011 14:36:46 GMT Prostate cancer cells are more likely to spread to other parts of the body if a specific gene quits functioning normally, as per new data from scientists at UT Southwestern Medical Center. Certain prostate cancer cells can be held in check by the DAB2IP gene. The gene's product, the DABIP protein, acts as scaffolding that prevents a number of other proteins involved in the progression of prostate cancer cells from over-activation. When those cells lose the DAB2IP protein, however, they break free and are able to metastasize, or spread, drastically increasing the risk of cancer progression in other organs as the cells travel through the bloodstream or lymph system........ ]]> http://medicineworld.org/stories/lead/1-2010/prostate-cancer-is-treated-differently.html http://medicineworld.org/stories/lead/1-2010/prostate-cancer-is-treated-differently.html Fri, 29 Apr 2011 14:36:46 GMT Scientists at Moores Cancer Center at the University of California, San Diego and his colleagues have observed that prostate cancer therapys varied significantly between county hospitals and private providers. Patients treated in county hospitals are more likely to undergo surgery while patients treated in private facilities tend to receive radiation or hormone treatment. These findings were published online by the journal Cancer on January 25........ ]]> http://medicineworld.org/stories/lead/11-2009/prostate-biopsy-is-not-always-necessary.html http://medicineworld.org/stories/lead/11-2009/prostate-biopsy-is-not-always-necessary.html Fri, 29 Apr 2011 14:36:46 GMT Scientists at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men appears to be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy........ ]]> http://medicineworld.org/stories/lead/11-2009/size-and-shape-of-the-blood-vessels.html http://medicineworld.org/stories/lead/11-2009/size-and-shape-of-the-blood-vessels.html Fri, 29 Apr 2011 14:36:46 GMT A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous therapy, or slowly, allowing treatment and its risks to be safely delayed? The answer may lie in the size and shape of the blood vessels that are visible within the cancer, as per research led by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in collaboration with the Harvard School of Public Health........ ]]>